Literature DB >> 27789182

Current Role of Radiotherapy for Renal-Cell Carcinoma: Review.

Natalia Dengina1, Ilya Tsimafeyeu2, Timur Mitin3.   

Abstract

Surgery is the standard of care for patients with renal-cell carcinoma (RCC). Radiotherapy (RT) can decrease the risk of local recurrence after surgery and can lead to excellent outcomes in patients unfit for surgery. We reviewed clinical experience with various forms of RT, including conventional fractionated RT and intraoperative radiotherapy (IORT) as adjunct to surgery, hypofractionated high-dose stereotactic body radiotherapy (SBRT), and particle therapy in unresectable RCC. We discuss future directions for using RT in the treatment of RCC. We encourage clinicians to incorporate RT modalities in prospective clinical trials.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Intraoperative radiotherapy; Particle therapy; Radioresistance; Radiosensitivity; Stereotactic body radiotherapy; Targeted therapy

Mesh:

Year:  2016        PMID: 27789182     DOI: 10.1016/j.clgc.2016.09.004

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  3 in total

Review 1.  Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.

Authors:  Girolamo Ranieri; Ilaria Marech; Artor Niccoli Asabella; Alessandra Di Palo; Mariangela Porcelli; Valentina Lavelli; Giuseppe Rubini; Cristina Ferrari; Cosmo Damiano Gadaleta
Journal:  Int J Mol Sci       Date:  2017-09-09       Impact factor: 5.923

2.  Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study.

Authors:  Natalia Dengina; Timur Mitin; Sergey Gamayunov; Sufia Safina; Yuliya Kreinina; Ilya Tsimafeyeu
Journal:  ESMO Open       Date:  2019-10-13

3.  Preoperative stereotactic body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumour thrombus: study protocol for a single-arm cohort trial.

Authors:  Yunchong Liu; Zhuo Liu; Ran Peng; Ruotao Xiao; Junjie Wang; Hao Wang; Lulin Ma
Journal:  BMJ Open       Date:  2022-01-31       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.